Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 10/20 | 0.84 |
| ▸ | AKT2 | P31751 | 4/20 | 0.76 |
| ▸ | GSK3B | P49841 | 3/20 | 0.76 |
| ▸ | KIT | P10721 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079358 | 0.92 | JAK3 (1.00) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL2021330 | 0.92 | JAK3 (1.00) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL2022699 | 0.87 | AKT2 (0.78) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL1003408 | 0.87 | AKT2 (1.00) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL30673936 | 0.87 | AKT2 (1.00) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL2019251 | 0.87 | AKT2 (0.83) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL9966955 | 0.86 | LCK (0.75) | LCKJAK3AKT2GSK3BKIT | |
| Hydrochloric Acid SCHEMBL29036033 | 0.85 | AKT2 (0.97) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL2023475 | 0.85 | LCK (0.73) | LCKJAK3AKT2GSK3BKIT | |
| SCHEMBL4125661 | 0.84 | AKT2 (1.00) | LCKJAK3AKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | LCK 206/4885JAK3 1/4885AKT2 1555/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | LCK 206/4885JAK3 1/4885AKT2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.